89bio Revenue and Competitors

Location

#9242

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • 89bio's estimated annual revenue is currently $16.1M per year.(i)
  • 89bio's estimated revenue per employee is $155,000

Employee Data

  • 89bio has 104 Employees.(i)
  • 89bio grew their employee count by 49% last year.

89bio's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
CEOReveal Email/Phone
4
SVP, Commercial StrategyReveal Email/Phone
5
VP, Head CMCReveal Email/Phone
6
VP, People & CultureReveal Email/Phone
7
SVP, Finance & Principal Accounting OfficerReveal Email/Phone
8
VP, Clinical DevelpmentReveal Email/Phone
9
Head BiometricsReveal Email/Phone
10
SVP, R&D OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is 89bio?

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making

keywords:N/A

N/A

Total Funding

104

Number of Employees

$16.1M

Revenue (est)

49%

Employee Growth %

N/A

Valuation

N/A

Accelerator

89bio News

2022-03-30 - 89bio (NASDAQ:ETNB) Announces Quarterly Earnings Results

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver...

2022-03-30 - 89bio gains a little more confidence in NASH treatment with ...

89bio has gained a little more confidence in its non-alcoholic steatohepatitis therapy after new data showed the treatment increased levels of a key hormone...

2022-03-22 - 89bio Reports Fourth Quarter and Full Year 2021 Financial ...

SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M1048%N/A
#2
$18.7M1045%N/A
#3
$9.4M1048%N/A
#4
$28.1M1040%N/A
#5
$28.1M10412%N/A